Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study

Human Psychopharmacology: Clinical and Experimental, 04/18/2012

No significant difference was seen between discontinuation rates of the two formulations. Higher baseline severity was associated with a lower discontinuation rate.


  • This 1–year, prospective, observational study included patients who had recently initiated treatment with olanzapine–coated tablets (OC) or the orodispersible (OD) formulation.
  • Primary endpoint was olanzapine discontinuation for any reason.
  • Clinical and functional status were also evaluated.


  • Out of 927 enrolled patients, 903 were included in the analyses (612 patients with schizophrenia, 291 with bipolar disorder).
  • Within 12 months, 46 of 903 patients discontinued olanzapine.
  • Most (95%) patients remained on olanzapine for 12 months with similar rates for patients with either diagnosis (94.5% for schizophrenia, 94.9% for bipolar disorder) and for both formulations (93.7% with OC, 95.3% with OD).
  • The only factor significantly associated with time to discontinuation was baseline disease severity.
  • Patients with more severe disease at baseline had a lower discontinuation risk.
  • There were significant improvements in functioning and well–being and non–significant improvements in therapeutic alliance and compliance.

Print Article Summary Cat 2 CME Report